Cargando…

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.

We have recently reported high clinical activity against advanced colorectal cancer of a regimen-alternating bolus FUra, modulated by methotrexate (MTX), and continuous infusion FUra, modulated by 6-s-leucovorin (6-s-LV). Considering the low toxicity of the bolus part of this regimen and our recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aschele, C., Guglielmi, A., Frassineti, G. L., Milandri, C., Amadori, D., Labianca, R., Vinci, M., Tixi, L., Caroti, C., Ciferri, E., Verdi, E., Rosso, R., Sobrero, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151226/ https://www.ncbi.nlm.nih.gov/pubmed/9461008

Ejemplares similares

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer
por: Sobrero, A, et al.
Publicado: (2001)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil
por: Guglielmi, A, et al.
Publicado: (2004)

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer – a phase II study
por: Tomlinson, Shannon K, et al.
Publicado: (2002)

Selecting a TNT Schedule in Locally Advanced Rectal Cancer: Can We Predict Who Actually Benefits?
por: Aschele, Carlo, et al.
Publicado: (2023)

In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
por: Peters, G. J., et al.
Publicado: (1988)

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
por: Passardi, Alessandro, et al.
Publicado: (2006)

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
por: Cascinu, S, et al.
Publicado: (2008)

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid
por: Correale, P, et al.
Publicado: (2003)

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
por: Deng, Lifen, et al.
Publicado: (2013)

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
por: De Placido, S, et al.
Publicado: (2005)

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen
por: Cascinu, S, et al.
Publicado: (2002)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
por: Cascinu, S, et al.
Publicado: (1999)

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
por: Kano, Y., et al.
Publicado: (1996)

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
por: Graziano, F, et al.
Publicado: (2003)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
por: Ardizzoni, A, et al.
Publicado: (1999)

Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
por: Cascinu, S., et al.
Publicado: (1998)

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
por: Osterlund, P., et al.
Publicado: (2022)

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial
por: Barone, C, et al.
Publicado: (2007)

Scheduling for Responsive Grids
por: Germain-Renaud, C, et al.
Publicado: (2008)

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
por: Gabra, H., et al.
Publicado: (1996)

Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer
por: Lortholary, A, et al.
Publicado: (2003)

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

FESTIval: A versatile framework for conducting experimental evaluations of spatial indices
por: Carniel, Anderson C., et al.
Publicado: (2019)

Scheduling the powering tests
por: Barbero-Soto, E, et al.
Publicado: (2008)

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
por: Boni, C, et al.
Publicado: (2012)

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
por: Cutsem, E Van, et al.
Publicado: (2004)

Fluorouracil Catabolism in the Combination Treatment of Cyclophosphamide, Methotrexate and Fluorouracil
por: De Bruijn, Ernst A., et al.
Publicado: (1992)

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
por: Gusella, M, et al.
Publicado: (2009)

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity
por: Cianci, G, et al.
Publicado: (2003)

Predicting development of distant metastases and long-term outcome of locally advanced rectal cancer treated with neoadjuvant chemotherapy and radiation
por: Aschele, Carlo, et al.
Publicado: (2022)

Continuous 5-fluorouracil in the treatment of breast cancer.
por: Cameron, D. A., et al.
Publicado: (1994)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
por: Kuehr, Thomas, et al.
Publicado: (2004)

The switcher and the scheduler
por: Arnault, C, et al.
Publicado: (1987)

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours
por: Turner, N C, et al.
Publicado: (2010)

The multicentre south European study 'Helios'. I: Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin.
por: Zanetti, R., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_3n8lr1aepft2i5vued5ljmhhuv